Formycon AG (FYB.DE)
EUR 23.9
(5.99%)
EUR 23.9
(5.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.45 Million EUR | -93.79% |
| 2022 | 39.48 Million EUR | 299.98% |
| 2021 | -19.74 Million EUR | 46.67% |
| 2020 | -37.02 Million EUR | -67.43% |
| 2019 | -22.11 Million EUR | -201.46% |
| 2018 | -7.33 Million EUR | -62.88% |
| 2017 | -4.5 Million EUR | -50.4% |
| 2016 | -2.99 Million EUR | -381.09% |
| 2015 | -622.48 Thousand EUR | -115.47% |
| 2014 | -288.89 Thousand EUR | 67.88% |
| 2013 | -899.31 Thousand EUR | -322.59% |
| 2012 | -212.8 Thousand EUR | -173.89% |
| 2011 | 288 Thousand EUR | 121.01% |
| 2010 | -1.37 Million EUR | -19485.04% |
| 2009 | -7000.00 EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -29.75 Million EUR | 0.0% |
| 2023 Q2 | -28.05 Million EUR | 0.0% |
| 2023 FY | 2.45 Million EUR | -93.79% |
| 2023 Q4 | 2.45 Million EUR | 0.0% |
| 2022 FY | 39.48 Million EUR | 299.98% |
| 2022 Q2 | -9.21 Million EUR | 0.0% |
| 2022 Q4 | 39.48 Million EUR | 0.0% |
| 2021 FY | -19.74 Million EUR | 46.67% |
| 2021 Q2 | -33.47 Million EUR | 0.0% |
| 2021 Q4 | -20.62 Million EUR | 0.0% |
| 2020 Q2 | -19.99 Million EUR | 0.0% |
| 2020 FY | -37.02 Million EUR | -67.43% |
| 2020 Q4 | -42 Million EUR | 0.0% |
| 2019 FY | -22.11 Million EUR | -201.46% |
| 2019 Q2 | -7.48 Million EUR | 0.0% |
| 2019 Q4 | -22.11 Million EUR | 0.0% |
| 2018 FY | -7.33 Million EUR | -62.88% |
| 2018 Q4 | -7.33 Million EUR | 0.0% |
| 2018 Q2 | -4.84 Million EUR | 0.0% |
| 2017 Q2 | -3.44 Million EUR | 0.0% |
| 2017 FY | -4.5 Million EUR | -50.4% |
| 2017 Q4 | -4.5 Million EUR | 0.0% |
| 2016 FY | -2.99 Million EUR | -381.09% |
| 2016 Q2 | -5.81 Million EUR | 0.0% |
| 2016 Q4 | -2.99 Million EUR | 0.0% |
| 2015 Q4 | -622.48 Thousand EUR | 0.0% |
| 2015 Q2 | -4.72 Million EUR | 0.0% |
| 2015 FY | -622.48 Thousand EUR | -115.47% |
| 2014 Q2 | -552.52 Thousand EUR | 0.0% |
| 2014 Q4 | -288.89 Thousand EUR | 0.0% |
| 2014 FY | -288.89 Thousand EUR | 67.88% |
| 2013 FY | -899.31 Thousand EUR | -322.59% |
| 2013 Q4 | -899.31 Thousand EUR | 0.0% |
| 2013 Q2 | -4.63 Million EUR | 0.0% |
| 2012 FY | -212.8 Thousand EUR | -173.89% |
| 2012 Q4 | -212.8 Thousand EUR | 0.0% |
| 2012 Q2 | 1.19 Million EUR | 0.0% |
| 2011 FY | 288 Thousand EUR | 121.01% |
| 2010 FY | -1.37 Million EUR | -19485.04% |
| 2009 FY | -7000.00 EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 100.021% |
| CureVac N.V. | -360.92 Million EUR | 100.679% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 99.571% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 99.571% |
| BRAIN Biotech AG | -693 Thousand EUR | 453.68% |
| Heidelberg Pharma AG | -37.6 Million EUR | 106.517% |
| Medigene AG | -5.72 Million EUR | 142.82% |